Novo Nordisk Deal History & Licensing Activity
Novo Nordisk is a large pharma headquartered in Denmark. Over the past three years, Novo Nordisk has been involved in 19 licensing and acquisition transactions, with a primary focus on Peptides (7 deals). The company currently has 50 active clinical trials, primarily in Metabolic.
Deals (12mo)
3
Active Trials
50
Top Modality
Peptides
Focus Area
Metabolic
Novo Nordisk Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Novo Nordisk in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| zaltenibart | Omeros | Other | Unknown | acquisition | Jul 18, 2026 |
| GLP-1/GIP/glucagon agonist | United Laboratories | Peptides | Unknown | collaboration | Jun 25, 2026 |
| once-monthly GLP-1 drug | Ascendis | Peptides | Preclinical | license |
Novo Nordisk Pipeline Focus
Therapeutic areas and modalities where Novo Nordisk is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Novo Nordisk Strategic Signals
Key indicators of Novo Nordisk's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
Novo Nordisk Clinical Pipeline
Novo Nordisk has 50 active clinical trials across 6 development phases.
1
Phase 4
2
Not Applicable
11
Unknown
17
Phase 1
5
Phase 2
14
Phase 3
See How Your Asset Matches Novo Nordisk's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Metabolic assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Cardiovascular Deal Benchmarks
Market sizing, deal terms, and competitive landscape for cardiovascular
Peptides Benchmarks
Upfront, milestone, and royalty benchmarks for peptides deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
About Novo Nordisk Licensing & Deal Activity
Novo Nordisk is a large pharma company based in Denmark that has been actively engaged in licensing transactions across the biopharma landscape. With 19 deals over the past three years, Novo Nordisk ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Novo Nordisk include Metabolic (59 deals and trials), Cardiovascular (6 deals and trials), Option Deals (3 deals and trials), and Hematology (1 deal and trial). In terms of modality, Novo Nordisk has shown particular interest in peptides, other, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Novo Nordisk and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Novo Nordisk's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.